• 1
    Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 2
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 7480.
  • 3
    Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34: 165173.
  • 4
    Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C–related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 18031809.
  • 5
    Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. US Public Health Services/Infectious Diseases Society of America. MMWR 1999; 48(R-10): 182.
  • 6
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. HEPATOLOGY 2002; 36(5 Suppl 1): S320.
  • 7
    Bräu N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, Frost KR, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin. HEPATOLOGY 2004; 39: 989998.
  • 8
    Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97100.
  • 8
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 10
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 11
    Chung RT, Anderson J, Alston B, Vallee M, Robbins G, Nevin T, et al. A randomized, controlled trial of pegylated interferon alpha-2s with ribavirin versus interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG 5071 [abstract LB15]. Ninth Conference on Retrovirology and Opportunistic Infections; February 24–28, 2002; Seattle, WA.
  • 12
    Perronne C, Carrat F, Bani S. RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin versus interferon alfa2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. In: XIVth World AIDS Conference. Barcelona, Spain, 7–12 July 2002 [abstract LbOr16].
  • 13
    Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 24912499.
  • 14
    Davis GL. Monitoring of viral levels during therapy of hepatitis C. HEPATOLOGY 2002; 36(5 Suppl 1 ): S145S151.